B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer

Jingqiang Wang, Takashi Kobayashi, Nicolas Floc'h, Carolyn Waugh Kinkade, Alvaro Aytes, David Dankort, Celine Lefebvre, Antonina Mitrofanova, Robert Cardiff, Martin McMahon, Andrea Califano, Michael M. Shen, Cory Abate-Shen

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAFV600E oncogene. These tissue-speci fic compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30% of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways.

Original languageEnglish (US)
Pages (from-to)4765-4776
Number of pages12
JournalCancer Research
Volume72
Issue number18
DOIs
StatePublished - Sep 15 2012

Fingerprint

Mitogen-Activated Protein Kinases
Phosphatidylinositol 3-Kinases
Prostatic Neoplasms
Prostate
Mitogen-Activated Protein Kinase 3
Mitogen-Activated Protein Kinase 1
Neoplasms
Cell Aging
Castration
Sirolimus
Tumor Burden
Oncogenes
Up-Regulation
Lymph Nodes
Bone Marrow
Neoplasm Metastasis
Lung
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Wang, J., Kobayashi, T., Floc'h, N., Kinkade, C. W., Aytes, A., Dankort, D., ... Abate-Shen, C. (2012). B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. Cancer Research, 72(18), 4765-4776. https://doi.org/10.1158/0008-5472.CAN-12-0820

B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. / Wang, Jingqiang; Kobayashi, Takashi; Floc'h, Nicolas; Kinkade, Carolyn Waugh; Aytes, Alvaro; Dankort, David; Lefebvre, Celine; Mitrofanova, Antonina; Cardiff, Robert; McMahon, Martin; Califano, Andrea; Shen, Michael M.; Abate-Shen, Cory.

In: Cancer Research, Vol. 72, No. 18, 15.09.2012, p. 4765-4776.

Research output: Contribution to journalArticle

Wang, J, Kobayashi, T, Floc'h, N, Kinkade, CW, Aytes, A, Dankort, D, Lefebvre, C, Mitrofanova, A, Cardiff, R, McMahon, M, Califano, A, Shen, MM & Abate-Shen, C 2012, 'B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer', Cancer Research, vol. 72, no. 18, pp. 4765-4776. https://doi.org/10.1158/0008-5472.CAN-12-0820
Wang, Jingqiang ; Kobayashi, Takashi ; Floc'h, Nicolas ; Kinkade, Carolyn Waugh ; Aytes, Alvaro ; Dankort, David ; Lefebvre, Celine ; Mitrofanova, Antonina ; Cardiff, Robert ; McMahon, Martin ; Califano, Andrea ; Shen, Michael M. ; Abate-Shen, Cory. / B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. In: Cancer Research. 2012 ; Vol. 72, No. 18. pp. 4765-4776.
@article{59ffc94c8fbf4868acdc4ad412ac3aac,
title = "B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer",
abstract = "Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAFV600E oncogene. These tissue-speci fic compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30{\%} of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways.",
author = "Jingqiang Wang and Takashi Kobayashi and Nicolas Floc'h and Kinkade, {Carolyn Waugh} and Alvaro Aytes and David Dankort and Celine Lefebvre and Antonina Mitrofanova and Robert Cardiff and Martin McMahon and Andrea Califano and Shen, {Michael M.} and Cory Abate-Shen",
year = "2012",
month = "9",
day = "15",
doi = "10.1158/0008-5472.CAN-12-0820",
language = "English (US)",
volume = "72",
pages = "4765--4776",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - B-raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer

AU - Wang, Jingqiang

AU - Kobayashi, Takashi

AU - Floc'h, Nicolas

AU - Kinkade, Carolyn Waugh

AU - Aytes, Alvaro

AU - Dankort, David

AU - Lefebvre, Celine

AU - Mitrofanova, Antonina

AU - Cardiff, Robert

AU - McMahon, Martin

AU - Califano, Andrea

AU - Shen, Michael M.

AU - Abate-Shen, Cory

PY - 2012/9/15

Y1 - 2012/9/15

N2 - Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAFV600E oncogene. These tissue-speci fic compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30% of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways.

AB - Both the PI3K → Akt → mTOR and mitogen-activated protein kinase (MAPK) signaling pathways are often deregulated in prostate tumors with poor prognosis. Here we describe a new genetically engineered mouse model of prostate cancer in which PI3K-Akt-mTOR signaling is activated by inducible disruption of PTEN, and extracellular signal-regulated kinase 1/2 (ERK1/2) MAPK signaling is activated by inducible expression of a BRAFV600E oncogene. These tissue-speci fic compound mutant mice develop lethal prostate tumors that are inherently resistant to castration. These tumors bypass cellular senescence and disseminate to lymph nodes, bone marrow, and lungs where they form overt metastases in approximately 30% of the cases. Activation of PI3K → Akt → mTOR and MAPK signaling pathways in these prostate tumors cooperate to upregulate c-Myc. Accordingly, therapeutic treatments with rapamycin and PD0325901 to target these pathways, respectively, attenuate c-Myc levels and reduce tumor and metastatic burden. Together, our findings suggest a generalized therapeutic approach to target c-Myc activation in prostate cancer by combinatorial targeting of the PI3K → Akt → mTOR and ERK1/2 MAPK signaling pathways.

UR - http://www.scopus.com/inward/record.url?scp=84866424540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866424540&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-12-0820

DO - 10.1158/0008-5472.CAN-12-0820

M3 - Article

C2 - 22836754

AN - SCOPUS:84866424540

VL - 72

SP - 4765

EP - 4776

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 18

ER -